Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2018
At a glance
- Drugs Human dermal fibroblasts-SpinalCyte (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions
- 17 May 2018 According to a SpinalCyte media release, the company announced that posters from this trial will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018.
- 12 Apr 2018 According to a SpinalCyte media release, company has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to expand this ongoing study.
- 03 Apr 2018 According to a SpinalCyte media release, Preliminary six-month MRI data on 18 patients has been completed with an independent radiological expert providing MRI analysis.